ALT

Altimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.42
+0.48
+4.83%
Pre Market: 10.42 0 0.00% 08:01 07/06 EDT
OPEN
9.65
PREV CLOSE
9.94
HIGH
10.75
LOW
9.37
VOLUME
1.64M
TURNOVER
--
52 WEEK HIGH
12.74
52 WEEK LOW
1.510
MARKET CAP
209.56M
P/E (TTM)
-6.8198
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALT stock price target is 13.00 with a high estimate of 13.00 and a low estimate of 13.00.

EPS

ALT News

More
Leaf Group, Forma Therapeutics See Activist Action
marketwatch.com · 3d ago
Smaller cap COVID-19 vaccine players under pressure on Pfizer data
Seeking Alpha - Article · 4d ago
FDA guides on COVID-19 vaccine approval criteria
Seeking Alpha - Article · 5d ago
Coronavirus Vaccine Update, June 29
Seeking Alpha - Article · 5d ago
Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield, a Single Dose Intranasal Anthrax Vaccine Candidate
GlobeNewswire · 6d ago
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 6d ago
Dosing underway in Altimmune early-stage NasoShield trial
Seeking Alpha - Article · 6d ago
Altimmune Announces Dosing of First Patient In Phase 1b Clinical Trial Of NasoShield, A Single Dose Intranasal Anthrax Vaccine Candidate
Benzinga · 6d ago

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About ALT

Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.
More

Webull offers kinds of Altimmune Inc stock information, including NASDAQ:ALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALT stock methods without spending real money on the virtual paper trading platform.